FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:1041-1048 October 3, 1996 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Methotrexate, a folic acid antagonist, is used extensively not only for the treatment of cancer but also for the treatment of rheumatoid arthritis, psoriasis, and autoimmune disease and for the prevention of graft-versus-host disease after transplantation. The drug is also used as an abortifacient.^1,2 Other folate antagonists are used to treat bacterial infections (trimethoprim), malaria (pyrimethamine), and Pneumocystis carinii infection (trimetrexate with leucovorin).^3,4 As with other drugs used to treat infectious diseases or cancers, the development of resistance limits the effectiveness of these folate antagonists. An understanding of the mechanisms of resistance to this class of drugs is important for . . . [Full Text of this Article]

Mechanisms of Action

Mechanisms of Resistance to Methotrexate

Acquired Resistance to Methotrexate

Intrinsic Resistance to Methotrexate

Tumor-Suppressor Genes and Methotrexate Resistance

Strategies to Overcome or Exploit Methotrexate Resistance

Conclusions

Source Information

From the Departments of Pediatrics (R.G., T.T.) and Molecular Pharmacology and Therapeutics (E.G., M.W., D.B., J.R.B.), Memorial Sloan-Kettering Cancer Center, New York.

Address reprint requests to Dr. Bertino at the Department of Molecular Pharmacology and Therapeutics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.

References

This article has been cited by other articles:

• Al-Shakfa, F., Dulucq, S., Brukner, I., Milacic, I., Ansari, M., Beaulieu, P., Moghrabi, A., Laverdiere, C., Sallan, S. E., Silverman, L. B., Neuberg, D., Kutok, J. L., Sinnett, D., Krajinovic, M. (2009). DNA Variants in Region for Noncoding Interfering Transcript of Dihydrofolate Reductase Gene and Outcome in Childhood Acute Lymphoblastic Leukemia. Clin. Cancer Res. 15: 6931-6938 [Abstract] [Full Text]  
• Bertino, J. R. (2008). Transfer of drug resistance genes into hematopoietic stem cells for marrow protection.. The Oncologist 13: 1036-1042 [Full Text]  
• Moorman, A. V. (2008). One man's dose, another man's poison. Blood 111: 3303-3304 [Full Text]  
• Dulucq, S., St-Onge, G., Gagne, V., Ansari, M., Sinnett, D., Labuda, D., Moghrabi, A., Krajinovic, M. (2008). DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood 111: 3692-3700 [Abstract] [Full Text]  
• Mishra, P. J., Humeniuk, R., Mishra, P. J., Longo-Sorbello, G. S. A., Banerjee, D., Bertino, J. R. (2007). A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl. Acad. Sci. USA 104: 13513-13518 [Abstract] [Full Text]  
• Matheson, E. C., Hogarth, L. A., Case, M. C., Irving, J. A.E., Hall, A. G. (2007). DHFR and MSH3 co-amplification in childhood acute lymphoblastic leukaemia, in vitro and in vivo. Carcinogenesis 28: 1341-1346 [Abstract] [Full Text]  
• Ge, Y., Haska, C. L., LaFiura, K., Devidas, M., Linda, S. B., Liu, M., Thomas, R., Taub, J. W., Matherly, L. H. (2007). Prognostic Role of the Reduced Folate Carrier, the Major Membrane Transporter for Methotrexate, in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group. Clin. Cancer Res. 13: 451-457 [Abstract] [Full Text]  
• Liu, M., Ge, Y., Payton, S. G., Aboukameel, A., Buck, S., Flatley, R. M., Haska, C., Mohammad, R., Taub, J. W., Matherly, L. H. (2006). Transcriptional Regulation of the Human Reduced Folate Carrier in Childhood Acute Lymphoblastic Leukemia Cells. Clin. Cancer Res. 12: 608-616 [Abstract] [Full Text]  
• van Trommel, N. E., Massuger, L. F., Schijf, C. P., ten Kate-Booij, M. J., Sweep, F. C., Thomas, C. M. (2006). Early Identification of Resistance to First-Line Single-Agent Methotrexate in Patients With Persistent Trophoblastic Disease. JCO 24: 52-58 [Abstract] [Full Text]  
• Cole, P. D., Drachtman, R. A., Smith, A. K., Cate, S., Larson, R. A., Hawkins, D. S., Holcenberg, J., Kelly, K., Kamen, B. A. (2005). Phase II Trial of Oral Aminopterin for Adults and Children with Refractory Acute Leukemia. Clin. Cancer Res. 11: 8089-8096 [Abstract] [Full Text]  
• Rothem, L., Berman, B., Stark, M., Jansen, G., Assaraf, Y. G. (2005). The Reduced Folate Carrier Gene Is a Novel Selectable Marker for Recombinant Protein Overexpression. Mol. Pharmacol. 68: 616-624 [Abstract] [Full Text]  
• Spees, W. M., Gade, T. P.F., Yang, G., Tong, W. P., Bornmann, W. G., Gorlick, R., Koutcher, J. A. (2005). An 19F Magnetic Resonance-Based In Vivo Assay of Solid Tumor Methotrexate Resistance: Proof of Principle. Clin. Cancer Res. 11: 1454-1461 [Abstract] [Full Text]  
• Winick, N. J., Carroll, W. L., Hunger, S. P. (2004). Childhood Leukemia -- New Advances and Challenges. NEJM 351: 601-603 [Full Text]  
• Flatley, R. M., Payton, S. G., Taub, J. W., Matherly, L. H. (2004). Primary Acute Lymphoblastic Leukemia Cells Use a Novel Promoter and 5'Noncoding Exon for the Human Reduced Folate Carrier That Encodes a Modified Carrier Translated from an Upstream Translational Start. Clin. Cancer Res. 10: 5111-5122 [Abstract] [Full Text]  
• Spees, W. M., Yang, G., Veach, D., Rubio, M. B., Koutcher, J. A., Bornmann, W. (2003). A fluorine-labeled methotrexate as a probe for monitoring tumor antifolate pharmacokinetics: Synthesis, in vitro cytotoxicity, and pilot in vivo 19F magnetic resonance spectra. Molecular Cancer Therapeutics 2: 933-939 [Abstract] [Full Text]  
• Sowers, R., Toguchida, J., Qin, J., Meyers, P. A., Healey, J. H., Huvos, A., Banerjee, D., Bertino, J. R., Gorlick, R. (2003). mRNA Expression Levels of E2F Transcription Factors Correlate with Dihydrofolate Reductase, Reduced Folate Carrier, and Thymidylate Synthase mRNA Expression in Osteosarcoma. Molecular Cancer Therapeutics 2: 535-541 [Abstract] [Full Text]  
• Yang, R., Sowers, R., Mazza, B., Healey, J. H., Huvos, A., Grier, H., Bernstein, M., Beardsley, G. P., Krailo, M. D., Devidas, M., Bertino, J. R., Meyers, P. A., Gorlick, R. (2003). Sequence Alterations in the Reduced Folate Carrier Are Observed in Osteosarcoma Tumor Samples. Clin. Cancer Res. 9: 837-844 [Abstract] [Full Text]  
• Laverdiere, C., Chiasson, S., Costea, I., Moghrabi, A., Krajinovic, M. (2002). Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100: 3832-3834 [Abstract] [Full Text]  
• Panetta, J. C., Wall, A., Pui, C.-H., Relling, M. V., Evans, W. E. (2002). Methotrexate Intracellular Disposition in Acute Lymphoblastic Leukemia: A Mathematical Model of {gamma}-Glutamyl Hydrolase Activity. Clin. Cancer Res. 8: 2423-2429 [Abstract] [Full Text]  
• Worm, J., Kirkin, A. F., Dzhandzhugazyan, K. N., Guldberg, P. (2001). Methylation-dependent Silencing of the Reduced Folate Carrier Gene in Inherently Methotrexate-resistant Human Breast Cancer Cells. J. Biol. Chem. 276: 39990-40000 [Abstract] [Full Text]  
• Trippett, T. M., Garcia, S., Manova, K., Mody, R., Cohen-Gould, L., Flintoff, W., Bertino, J. R. (2001). Localization of a Human Reduced Folate Carrier Protein in the Mitochondrial as Well as the Cell Membrane of Leukemia Cells. Cancer Res. 61: 1941-1947 [Abstract] [Full Text]  
• Belur, L. R., Boelk-Galvan, D., Diers, M. D., McIvor, R. S., Zimmerman, C. L. (2001). Methotrexate Accumulates to Similar Levels in Animals Transplanted with Normal versus Drug-resistant Transgenic Marrow. Cancer Res. 61: 1522-1526 [Abstract] [Full Text]  
• Mahoney, D. H. Jr, Shuster, J. J., Nitschke, R., Lauer, S., Steuber, C. P., Camitta, B. (2000). Intensification With Intermediate-Dose Intravenous Methotrexate Is Effective Therapy for Children With Lower-Risk B-Precursor Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study. JCO 18: 1285-1294 [Abstract] [Full Text]  
• Jarvinen, T. A. H., Tanner, M., Rantanen, V., Barlund, M., Borg, A., Grenman, S., Isola, J. (2000). Amplification and Deletion of Topoisomerase II{alpha} Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer. Am. J. Pathol. 156: 839-847 [Abstract] [Full Text]  
• Felix, C. A., Lange, B. J., Chessells, J. M. (2000). Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000. ASH Education Book 2000: 285-302 [Abstract] [Full Text]  
• Rots, M. G., Pieters, R., Peters, G. J., van Zantwijk, C. H., Mauritz, R., Noordhuis, P., Willey, J. C., Hahlen, K., Creutzig, U., Janka-Schaub, G., Kaspers, G. J.L., Veerman, A. J.P., Jansen, G. (1999). Circumvention of Methotrexate Resistance in Childhood Leukemia Subtypes by Rationally Designed Antifolates. Blood 94: 3121-3128 [Abstract] [Full Text]  
• Hooijberg, J. H., Broxterman, H. J., Kool, M., Assaraf, Y. G., Peters, G. J., Noordhuis, P., Scheper, R. J., Borst, P., Pinedo, H. M., Jansen, G. (1999). Antifolate Resistance Mediated by the Multidrug Resistance Proteins MRP1 and MRP2. Cancer Res. 59: 2532-2535 [Abstract] [Full Text]  
• Guo, W., Healey, J. H., Meyers, P. A., Ladanyi, M., Huvos, A. G., Bertino, J. R., Gorlick, R. (1999). Mechanisms of Methotrexate Resistance in Osteosarcoma. Clin. Cancer Res. 5: 621-627 [Abstract] [Full Text]  
• Belkov, V. M., Krynetski, E. Y., Schuetz, J. D., Yanishevski, Y., Masson, E., Mathew, S., Raimondi, S., Pui, C.-H., Relling, M. V., Evans, W. E. (1999). Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation. Blood 93: 1643-1650 [Abstract] [Full Text]  
• Rots, M. G., Pieters, R., Peters, G. J., Noordhuis, P., van Zantwijk, C. H., Kaspers, G. J.L., Hahlen, K., Creutzig, U., Veerman, A. J.P., Jansen, G. (1999). Role of Folylpolyglutamate Synthetase and Folylpolyglutamate Hydrolase in Methotrexate Accumulation and Polyglutamylation in Childhood Leukemia. Blood 93: 1677-1683 [Abstract] [Full Text]  
• Jansen, G., Mauritz, R., Drori, S., Sprecher, H., Kathmann, I., Bunni, M., Priest, D. G., Noordhuis, P., Schornagel, J. H., Pinedo, H. M., Peters, G. J., Assaraf, Y. G. (1998). A Structurally Altered Human Reduced Folate Carrier with Increased Folic Acid Transport Mediates a Novel Mechanism of Antifolate Resistance. J. Biol. Chem. 273: 30189-30198 [Abstract] [Full Text]  
• Marra, G., Iaccarino, I., Lettieri, T., Roscilli, G., Delmastro, P., Jiricny, J. (1998). Mismatch repair deficiency associated with overexpression of the MSH3 gene. Proc. Natl. Acad. Sci. USA 95: 8568-8573 [Abstract] [Full Text]  
• Zhao, R., Assaraf, Y. G., Goldman, I. D. (1998). A Reduced Folate Carrier Mutation Produces Substrate-dependent Alterations in Carrier Mobility in Murine Leukemia Cells and Methotrexate Resistance with Conservation of Growth in 5-Formyltetrahydrofolate. J. Biol. Chem. 273: 7873-7879 [Abstract] [Full Text]  
• Longo, G. S.A., Gorlick, R., Tong, W. P., Ercikan, E., Bertino, J. R. (1997). Disparate Affinities of Antifolates for Folylpolyglutamate Synthetase From Human Leukemia Cells. Blood 90: 1241-1245 [Abstract] [Full Text]